Chronic Myeloid Leukaemia (CML) patients in England who are resistant or intolerant to second generation tyrosine kinase inhibitor (TKI) therapies are on the brink of getting full-access to Incyte’s Iclusig on the NHS following a nod from NICE.
Read More
Takeda has now completion of its $5.2 billion acquisition of ARIAD Pharmaceuticals, in a deal that significantly boosts the Japanese drugmaer’s global cancer portfolio.
Read More
Draft guidelines published by the National Institute for Health and Care Excellence back the routine use of Incyte’s Iclusig on the NHS to treat some patients with chronic myeloid leukaemia and acute lymphoblastic leukaemia.
Read More
Takeda has announced its intention to buy US drugmaker Ariad for around $5.2 billion, in a move designed to boost its oncology offering.
Read More
